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Background: Gallbladder cancer (GBC) is an often lethal malignancy with variable distribution. Incidence 
in the United States is low. However, in areas of Central/South America, Central Europe, Japan, and the 
Indian subcontinent, GBC is a major cause of cancer death. Cholecystectomy is safe and commonly 
performed worldwide. Thus, prophylactic cholecystectomy (PCCY) has been proposed in regions with 
endemic GBC. We developed a simple decision model to assist caregivers in determining the optimal 
strategy for managing GBC based on local incidence and technological capabilities.  
 
Methods: Rates of disease and outcomes were derived from a review of the literature.  Using TreeAge-
Pro software, a decision model was created to simulate expected health outcomes for populations with 
high GBC incidence, following 3 treatment strategies: no early intervention, one-time screening 
ultrasound (US), or PCCY. Lifetime cancer-specific survival was the outcome of interest. Sensitivity 
analyses were performed to determine threshold values.  
 
Results: Based on our model, populations where lifetime risk of GBC exceeds 0.4% may benefit from 
early intervention by US or PCCY. Two-way sensitivity analysis shows that over a relatively narrow range 
of disease incidence, US may be favored if sensitivity exceeds 50%. In many cases where lifetime risk 
exceeds 1%, PCCY may improve survival. 
 
Conclusions: GBC varies in incidence, but affects many 
individuals in some populations in the Americas. The 
lethality of GBC may justify aggressive public health 
intervention including screening or prophylactic 
cholecystectomy. Decision analysis models using best-
available evidence may help determine the optimal 
treatment of individuals at risk for GBC.  
 
  
 
Figure: Two-way sensitivity analysis demonstrating 
optimal strategies with varying risk of disease and 
ultrasound sensitivity.  
